Skip to content
Research Article Open access CC BY 4.0

Knowledge Level and Perceptions of Pharmacists and Prescribers Regarding Boxed Warnings

Michael L. Adams, Wesley D. Rich, Valerie B. Clinard

Journal of Advances in Medical and Pharmaceutical Sciences · pp. 1–11 · Published 12 Oct 2017

10.9734/JAMPS/2017/36666

Abstract

Background: Black box warnings indicating harmful or potentially fatal adverse events are required by the Food and Drug Administration on certain drugs and chemical entities; however it is unclear if prescribing and dispensing habits are impacted by these warnings. This study investigates the knowledge and perceptions of prescribers and pharmacists regarding black box warnings. Methods: A cross-sectional survey of self-reported behavior related to black box warnings was administered to prescribers and pharmacists across North Carolina between October 2010 and January 2011. Results: A total of 867 pharmacists and prescribers completed the survey, including 715 pharmacists and 152 prescribers. Of the respondents, 54% were female and 92% described their ethnicity as Caucasian. Overall, pharmacists reported a greater change in behavior than did prescribers in relation to the presence of a boxed warning (P < .01). Pharmacists also demonstrated a significantly greater overall knowledge of boxed warnings compared to prescribers (P < .01).  No differences in reported behavior or knowledge were observed between prescribers and pharmacists based on demographic factors.  Limitations: Solicitation through professional association mailing lists resulting in low response rates may impact findings. Conclusion: Overall knowledge on information pertaining to boxed warnings was lacking.  Impact in clinical practice due to the lack of understanding regarding boxed warnings may put patients at increased risk. To improve the overall knowledge of black boxed warnings, the FDA should adopt develop a publicly available central repository for all black box warnings. Curricula in schools of medicine and pharmacy as well as professional continuing education should include a focus on boxed warnings.  

Boxed warning drug regulation labeling knowledge prescribing behavior dispensing behavior

References (17)

  1. 1 Lactic Acidosis in Patients with Diabetes Treated with Metformin [DOI]
  2. 2 Contraindicated Use of Cisapride [DOI]
  3. 3 Persisting Decline in Depression Treatment After FDA Warnings [DOI]
  4. 4 Effects of Food and Drug Administration Warnings on Antidepressant Use in a National Sample [DOI]
  5. 5 Contraindications to metformin therapy in patients with Type 2 diabetes—a population‐based study of adherence to prescribing guidelines [DOI]
  6. 6 Liver Enzyme Monitoring in Patients Treated With Troglitazone [DOI]
  7. 7 Metformin and Thiazolidinedione Use in Medicare Patients With Heart Failure [DOI]
  8. 8 Should Physicians Address Patients' Spiritual Needs? [DOI]
  9. 9 Black Box Warning Contraindicated Comedications: Concordance Among Three Major Drug Interaction Screening Programs [DOI]
  10. 10 Pediatric Prescribing Practices and the FDA Black-box Warning on Antidepressants [DOI]
  11. 11 American Samoan women's health: experiences and attitudes toward breast and cervical cancer screening.
  12. 12 Therapeutic Drug Monitoring of Mood Stabilizers in Medicaid Patients With Bipolar Disorder [DOI]
  13. 13 Pediatric Antidepressant Use After The Black-Box Warning [DOI]
  14. 14 Risk Management Policy and Black-Box Warnings [DOI]
  15. 15 Boxed warning inconsistencies between drug information resources and the prescribing information [DOI]
  16. 16 Messages about Black-Box Warnings [DOI]
  17. 17 Pharmacy Students' Knowledge of Black Box Warnings [DOI]

Cited by 3

Evaluation of healthcare professionals' understanding of fluoroquinolones' safety profile, usage, and boxed warnings in Pakistan

Muhammad Abbas, Kashif Kashmiri, Inayat Ur Rehman · Journal of Pharmaceutical Policy and Practice · 2023

Assessment of Knowledge Regarding Safety Profile, Use, and Boxed Warnings of Fluoroquinolones Among Healthcare Professionals in Saudi Arabia: A Potential Implication for Drug Regulatory Authorities

Tauqeer Hussain Mallhi, Abdullah Salah Alanazi, Yusra Habib Khan · Frontiers in Medicine · 2022

Showing 2 of 3 known citations — external sources report more than can currently be individually listed.

Article metrics

Real usage data collected on this platform.

31

Page views

0

PDF downloads

8

Outbound clicks

3

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.